A federal program that has kept pricing steadier for standalone Medicare prescription drug plans is set to lapse at the end of this year, and the government has confirmed it will not renew it. The Centers for Medicare & Medicaid Services says plan sponsors have gathered enough experience pricing under Medicare’s redesigned drug benefit to operate without that extra support, so standalone plans will price their 2027 coverage under what the agency calls “traditional market conditions” for the first time since the redesign took effect. Alongside that announcement, CMS released the number that will anchor next year’s Part D bidding cycle: a national average monthly bid of $296.05. The agency has not said what that bid means for any individual retiree’s premium, and this article does not speculate on that either.
The Part D Premium Stabilization Demonstration Reaches Its End
The program ending is the Part D Premium Stabilization Demonstration, a voluntary arrangement CMS opened to standalone prescription drug plan sponsors, insurers that sell drug-only coverage apart from a Medicare Advantage plan, beginning in calendar year 2025. CMS built the demonstration to blunt the pricing volatility that followed the Inflation Reduction Act’s overhaul of the Part D benefit, a rewrite that changed how much plan sponsors, the federal government and drug manufacturers each cover once a beneficiary’s drug spending crosses certain thresholds. Standalone plans had shown some of the sharpest swings under that new structure, which is why CMS offered sponsors the extra support in the first place.
In a fact sheet dated July 28, 2026, CMS said its review of contract-year 2027 bid data found that sponsors have gathered enough experience under the redesigned benefit to support their own pricing assumptions without additional help, and that the agency will discontinue the demonstration at the end of calendar year 2026. That timing means every standalone Part D plan will price its 2027 coverage under ordinary market conditions for the first time since the IRA’s redesign took hold, with no announced plan from CMS to extend or replace the stabilization support.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
What the $296.05 Bid Actually Measures
The figure CMS published alongside the demonstration’s end, $296.05, is the 2027 national average monthly bid amount, or NAMBA. It is not a retail premium, and it was never designed to be read as one. CMS defines the NAMBA as an enrollment-weighted average of every Part D plan’s bid for the basic drug benefit, with each plan’s bid weighted according to how many people are enrolled in it. The government uses that weighted average specifically to calculate how much subsidy it contributes toward each plan’s basic-benefit costs, not to set what any household actually pays.
CMS’s own fact sheet does not translate the bid average into a specific dollar change for any individual’s premium, and nothing in the agency’s release supports doing so. Plan-level premiums vary by sponsor, region, drug formulary and cost-sharing tier, and CMS has said the complete picture, the finalized 2027 landscape and final average premiums, will not be public until sponsors have locked in their offerings later this year.
A Separate, Statutory Cap Still Applies to the Base Premium
Distinct from the expiring demonstration, CMS also set the 2027 base beneficiary premium, the starting point sponsors use before calculating their own plan-specific basic premium, at $41.33. That figure comes from a statutory formula built on a percentage of sponsor bids and estimated reinsurance costs tied to the required minimum level of coverage, known as the basic benefit.
That base premium carries a protection written into the Inflation Reduction Act itself, separate from the demonstration now winding down: the law caps the year-over-year increase in the base beneficiary premium at no more than 6 percent annually from 2024 through 2029. CMS’s fact sheet confirms that cap remains in force for 2027, since the statutory limit and the ending demonstration address two different pieces of Part D’s pricing structure, one sets a floor-level national figure by law, the other was a voluntary support sponsors could opt into.
Final Premiums Land Before Sponsors Lock In Their 2027 Plans
CMS describes the July 28 release as preliminary technical bid information, intended to give Part D and Medicare Advantage sponsors time to finalize their 2027 offerings and prepare for Medicare’s open enrollment season. The agency said it will publish the complete 2027 Medicare Advantage and Part D landscape, along with final average premiums and other plan-specific detail, in mid-to-late September, once every sponsor’s offering is finalized.
Until that landscape becomes public, the outcome for any specific standalone plan remains unannounced. Standalone drug plans that operated inside the stabilization demonstration through 2026 will price independently for 2027, and whatever change follows for a particular plan will surface in that CMS-published, plan-level data rather than in the national bid figure the agency released July 28.
Why the Ending Support Matters for Standalone Plan Enrollees
Standalone prescription drug plans serve a large share of Medicare’s population that does not carry a Medicare Advantage plan, relying instead on original Medicare paired with a separate drug plan selected and renewed each year. For that group, the mechanics behind Part D pricing are not academic: it is the annual decision that determines what pharmacy network, drug list and monthly cost carries into the next calendar year.
CMS created the stabilization demonstration specifically because the Inflation Reduction Act’s redesign made standalone plan bids harder for sponsors to predict, and the agency’s own decision to let it lapse is itself evidence that CMS considers the redesign settled enough to stand without the extra support. Whether individual sponsors set their 2027 premiums higher, lower or unchanged from 2026 will only be confirmed in CMS’s own September landscape release, not in the bid figures the agency published July 28.
This article was produced with the assistance of AI and reviewed by The Financial Wire editorial team.
More Financial Reading
- What really happens to your joint savings account when you die?
- How many CDs can you park at 1 bank? FDIC rules you must know
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
